Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Regulatory News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of Major Holdings

5 Mar 2019 07:00

RNS Number : 8084R
ReNeuron Group plc
05 March 2019
 

TR-1: Standard form for notification of major holdings

 

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

ReNeuron Group PLC

LEI: 2138003TU12CQ5TZO137

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Details of person subject to the notification obligation

Name

Invesco Ltd.

City and country of registered office (if applicable)

1555 Peachtree Street NE, Suite 1800,

Atlanta, GA 30309 United States

4. Full name of shareholder(s) (if different from 3.)

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached:

01-03-2019

6. Date on which issuer notified (DD/MM/YYYY):

04-03-2019

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

9.89%

0

9.89%

31,646,186

Position of previous notification (if

applicable)

11.91%

0

11.91%

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

 

GB00BF5G6K95

Number of voting rights

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

 

 

3,132,955

 

9.89%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

3,132,955

9.89%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdate

Exercise/Conversion Period

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdat

Exercise/Conversion Period 

Physical or cash

settlement

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Invesco Asset

Management Ltd.

9.89%

0

9.89%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

Invesco (UK) Ltd.

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

 

11. Additional information

 

     

 

Place of completion

Henley-on-Thames

Date of completion

04-03-2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUGUUCWUPBGBC
Date   Source Headline
5th Mar 201912:56 pmRNSNotification of Major Holdings
5th Mar 20197:00 amRNSNotification of Major Holdings
5th Mar 20197:00 amRNSNotification of Major Holdings
28th Feb 20197:00 amRNSBlock Listing Review and Total Voting Rights
20th Feb 20197:00 amRNSPositive preliminary data in US retinal trial
31st Jan 20197:00 amRNSNew exosome production scale-up data presented
24th Jan 20197:00 amRNSFirst patient treated in US stroke trial
4th Jan 20197:00 amRNSReNeuron signs exosome collaboration
14th Dec 20187:00 amRNSInterim Results
20th Nov 20182:00 pmRNSNotification of Interim Results
18th Oct 20187:00 amRNSReNeuron's lead cell line shows further potential
28th Sep 20182:16 pmRNSDirector/PDMR Interest in Shares and Share Options
27th Sep 20183:02 pmRNSDirectors Share Purchases
19th Sep 20184:40 pmRNSSecond Price Monitoring Extn
19th Sep 20184:35 pmRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSBusiness development update
12th Sep 201811:40 amRNSResult of AGM
12th Sep 20187:00 amRNSAGM Trading Update
31st Aug 20187:00 amRNSBlock Listing Review and TVR
31st Jul 20183:25 pmRNSPosting of Annual Report & Notice of AGM
17th Jul 20187:00 amRNSNotification of Major Holdings
16th Jul 20183:39 pmRNSNotification of Major Holdings
16th Jul 20187:00 amRNSNotification of Major Holdings
13th Jul 201811:50 amRNSNotification of Major Holdings
12th Jul 20187:00 amRNSPreliminary Results
11th Jul 20187:00 amRNSSigns retinal stem cell exclusivity agreement
4th Jul 20182:15 pmRNSNotification of Preliminary Results
17th May 20187:00 amRNSCapital Markets Event
4th May 20187:00 amRNSExosome data presented at ISCT conference
30th Apr 20187:00 amRNSCapital Markets Event and Webcast
19th Apr 20187:00 amRNSWins grant for retinal cell therapy development
10th Apr 20181:00 pmRNSAppointment of US-based Chief Medical Officer
26th Mar 20187:00 amRNSProduct Development Update
1st Mar 20187:00 amRNSBlock Listing Review and TVR
16th Feb 20187:00 amRNSBlock Listing Application
13th Feb 201810:00 amRNSPositive pre-clinical data in nerve injury
26th Jan 20187:00 amRNSPhase II stroke data presented at AHA conference
23rd Jan 201811:06 amRNSApproval of Share Capital Reorganisation
11th Jan 20187:00 amRNSFurther re Share Capital Reorganisation
5th Jan 20187:00 amRNSProposed Share Capital Reorganisation
14th Dec 20177:00 amRNSInterim results
14th Dec 20177:00 amRNSStroke clinical trial regulatory approval in US
8th Dec 20177:00 amRNSReNeuron opens US office
13th Nov 201711:30 amRNSNotification of Interim Results
8th Nov 20177:00 amRNSRetinal disease clinical trial moves into Phase II
31st Oct 20177:00 amRNSPositive stroke clinical data & regulatory update
27th Oct 20177:00 amRNSWins further UK grant
11th Oct 20171:31 pmRNSPDMR Interest in Shares and Share Options
9th Oct 20177:00 amRNSPresentation of positive pre-clinical data
12th Sep 20177:00 amRNSDirectors' Interest in Shares and Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.